CORE D: HUMAN MAB CORE

核心 D：人 MAB 核心

• 批准号: 8364939
• 负责人: Kenneth Michael Smith
• 金额: $ 20.09万
• 依托单位: OKLAHOMA MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8364939
• 关键词: Acute; Affinity; Antibodies; Antibody Specificity; Antigens; Autoimmune Diseases; Centers of Research Excellence; Collaborations; Core Facility; Disease; Epitopes; Funding; Generations; Goals; Grant; Health; Health Sciences; Human; Immune response; Immunoglobulin-Secreting Cells; Immunotherapeutic agent; Individual; Infection; Influenza; Institution; Laboratories; Length; Mentors; National Center for Research Resources; Nature; Oklahoma; Polysaccharides; Principal Investigator; Process; Protocols documentation; Publishing; Research; Research Infrastructure; Research Personnel; Resources; Science; Services; Source; Streptococcus pneumoniae; Technology; Time; United States National Institutes of Health; Universities; Vaccination; anthrax lethal factor; cost; human disease; human monoclonal antibodies; interest; novel therapeutics; pathogen; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Our COBRE-initiated Human Monoclonal Antibody Core Facility at OMRF is one of the few laboratories in the world that produces fully-human, full-length, antigen-specific antibodies and the only one that provides this service to COBRE investigators. Our process for making influenza-specific antibodies has been recently published (Wrammert et al., Nature. 2008 May 29; 453(7195):667-71, and Smith et al., Nature Protocols 2009; 4(3):372-84) and represents a significant breakthrough in antibody technology. With COBRE support, we have recently expanded our antigens of interest and have produced high affinity, protective antibodies to anthrax lethal toxin and various S. pneumoniae coat polysaccharides. Our primary goal is to collaborate with other COBRE investigators to define human immune responses after vaccination and to generate human monoclonal antibodies to supplement their research. We will begin at OMRF and as time and resources allow, we will expand these services to investigators at the Oklahoma University Health Sciences Center (OUHSC), Oklahoma State University and other COBRE institutions outside Oklahoma. One such collaboration with the Ballard lab at OUHSC will allow us to evaluate the generation of antibody secreting cells after acute or reactivated infection, rather than vaccination. The ability to generate antibodies after natural infection will greatly increase the number of pathogen responses we can study. These antibodies will also give us a true snapshot of the contribution of antibodies to various protective epitopes in human disease. In all these cases, the antibodies produced will be explored as passive immunotherapeutics. Finally, we will investigate microarray and Biacore technologies for the rapid initial characterization of the antibodies produced. The ability to screen antibodies simultaneously for large numbers of antigens will also allow us to study the specificities of antibodies produced by individuals with autoimmune disorders. Overall, this Core will provide services which will allow COBRE investigators to produce new therapeutics and explore new scientific directions in a variety of human immune responses in health and disease.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 COBRE-Initiated Human Monoclonal Antibody Core Facility OMRF是世界上为数不多的能够生产 全人、全长、抗原特异性抗体， 一个为COBRE调查员提供这项服务的机构我们 最近，制造流感特异性抗体的方法已经被 发表（Wrammert等人，自然2008年5月29日; 453（7195）：667-71和Smith等人，2009年自然方案; 4（3）：372-84），并代表了一个重大突破， 抗体技术在COBRE的支持下， 扩大了我们感兴趣的抗原， 炭疽致死毒素的亲和性、保护性抗体和各种 S.肺炎球菌外壳多糖。 我们的首要目标是 与其他COBRE研究人员合作， 接种疫苗后产生免疫应答， 单克隆抗体来补充他们的研究。 我们将 开始在OMRF和时间和资源允许，我们将扩大 这些服务给俄克拉荷马州大学健康中心的调查人员 科学中心（OUHSC），俄克拉荷马州州立大学和其他 俄克拉荷马州外的COBRE机构。 这样的合作 与巴拉德实验室在OUHSC将使我们能够评估 急性或再活化后抗体分泌细胞的产生 感染，而不是接种疫苗。能够产生 自然感染后抗体会大大增加， 我们可以研究的病原体反应。 这些抗体也将 给我们一个真实的快照， 人类疾病中的各种保护性表位。 在所有这些情况下， 产生的抗体将作为被动的 免疫治疗 最后，我们将研究微阵列， Biacore技术用于快速初始表征 产生的抗体。筛选抗体的能力 同时产生大量抗原也将使我们能够 研究个体产生的抗体的特异性， 自身免疫性疾病总体而言，该核心将提供服务 这将使COBRE研究人员能够生产新的治疗方法， 并在各种人类免疫系统中探索新的科学方向， 健康和疾病的反应。